EXEL Stock: Price, Earnings History and SEC Filings
Exelixis, Inc. (EXEL) last traded at $69.39, up 4.82% on the latest session and up 18.8% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.85 against an analyst estimate of $0.79, a beat of 7.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
EXEL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.85 | $0.79 | +7.59% |
| Jun 2026 | Aug 5, 2026 | $0.82 | $0.75 | +9.33% |
| Mar 2026 | May 5, 2026 | $0.79 | $0.67 | +17.91% |
| Dec 2025 | Feb 10, 2026 | $0.88 | $0.68 | +29.41% |
EXEL beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How EXEL reacts to earnings
Across its last 8 earnings releases, EXEL moved 8.3% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | +4.82% |
| 2026-08-05 | After close | -7.94% |
| 2026-05-05 | After close | +9.64% |
| 2026-02-10 | After close | -0.09% |
| 2026-01-12 | After close | +0.05% |
| 2025-11-04 | After close | +6.52% |
| 2025-07-28 | After close | -16.78% |
| 2025-05-13 | After close | +20.84% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
EXEL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | $2.3B | $783M | $876M | 33.7% | $2.78 |
| 2025 | $2.2B | $521M | $672M | 24.0% | $1.76 |
| 2023 | $1.8B | $208M | $293M | 11.4% | $0.65 |
| 2022 | $1.6B | $182M | $335M | 11.3% | $0.56 |
| 2021 | $1.4B | $231M | $347M | 16.1% | $0.72 |
| 2020 | $968M | $321M | $514M | 33.2% | $1.02 |
| 2018 | $854M | $690M | $382M | 80.8% | $2.21 |
| 2017 | $452M | $154M | $144M | 34.1% | $0.49 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for EXEL
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 11, 2026Other events
- 8-K · Aug 31, 2026Other events
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · May 29, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Other events, Financial statements and exhibits
- DEF 14A · Apr 15, 2026
Insider filing activity
EXEL insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
EXEL news
- Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL)Oct 31, 2026 · finance.yahoo.com
- Exelixis (EXEL) Beats Q3 Estimates, Is The Stock Fully Priced?Oct 31, 2026 · finance.yahoo.com
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesOct 30, 2026 · finance.yahoo.com
- Exelixis (EXEL) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- What Exelixis (EXEL) Said on Its Q3 Earnings CallOct 30, 2026 · marketbeat.com
- Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesOct 29, 2026 · finance.yahoo.com
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Exelixis: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in January.